4 years ago BTX popped to $10 when first announcing the start of a cancer diagnostic program. Now that PanC-DX has proven successful and is nearing release we are at $2.70. Do the math!
Plus within the last four years we have spawned AST, grew patents to 700+, started multiple regen clinical trials, picked up deals with many including GE, acquired Geron ip, and still no debt. Lots to look forward to within the newt months, weeks, days....PanC-DX, Renevia product launch in EU, more partnerships, trial results, OncoCyte IPO. A triple is not unrealistic here.
GE/BTX will eventually rake in huge revenues with us owning the worlds % f the gold standard hESC's. Within a year I bet we will be in all the top universities biology labs.
Besides these GE/BTX products the real fun will begin after the Summer when we start preparing PanC-DX cancer diagnostic test kits. Things take a while so have patience. BTX has been built from scratch starting in 2007, we now have seven subsidiaries that are starting to ipo along with over 600 key stem cell patents. R&D phase continues but end of 2015 will mark the product to market phase with GE stem Cell kits AND PanC-DX.
2016.... Forget about it, talkin over $20 a share IMO